The Chhattisgarh health department is committed to a zero-tolerance policy regarding quality control. In line with this commitment, the department has issued a show-cause notice to M/s. Effi Parenterals, initiating proceedings to blacklist the company.
Prior to the distribution of medicines from warehouses to health institutions, the quality of supplied drugs is rigorously tested. Random samples from all batches supplied by vendors undergo quality testing in NABL-accredited labs. This process ensures that only medicines that pass the tests are distributed to health institutions.
As part of this procedure, Albendazole tablets IP 400 mg (Drug Code – D12) supplied by M/s. Effi Parenterals to the warehouse, with batches PGT25451, PGT25450, PGT25480, and PGT25229, were tested at the State Drug Testing and Research Laboratory, Raipur, before being sent to hospitals. The tests revealed that these batches failed. Adhering to the zero-tolerance policy on quality, a show-cause notice has been issued to the firm, with the intention of blacklisting it. The firm has also been instructed to recall all failed batches from the medicine warehouses.
In addition to these batches, the firm had previously supplied 14 batches of Albendazole tablets IP 400 mg, which were distributed to health institutions after passing NABL test reports.
